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A recent Commentator issue (No. 423)
authored by Evert Van der Sluis described the
current status of biotechnology, including some of
its potential costs and benefits. Consumer
concerns and some principles for analyzing
biotechnology were addressed. In this
Commentator issue, I describe how the
'Precautionary Principie' is beginning to be used in
some parts of the world, particularly In Europe, to
address some of the concerns identified by Van der
Sluis. The kind of 'biotechnology' I refer to here is
genetic engineering that involves the transfer of
functional genes from one organism to another—
creating, in effect, 'transgenic' plants or animals.
Therefore, I will use the terms 'biotechnology',
'genetic engineering', and Iransgenic technology'
interchangeably.
There Is a tendency among some groups
and individuals to suggest that current contro
versies about genetic engineering technology in
agriculture are due largely to an uninformed public
and distortions in the media. That simplistic view
ignores three central facts. First, new technologies
inherently canry many unknown consequences, and
that is especially true for a technology with such
profoundly new and different elements as
transgenic technology. Second, most new techno
logies positively impact some individuals and
groups while negatively Impacting others. One
need only consider the history of the Industrial
Revolution for that to be abundantly apparent. And
finally, different Individuals and cultures vary In their
'values', especially as they weigh the importance of
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potential benefits of a new technology in relation to
that technology's perceived costs and risks.
These facts must all be taken into account
In the development of public policies for biotech
nologies in democratic societies. That can only be
done by taking a systems perspective. A systems
perspective allows one to view the various ways in
which different stakeholders in society are affected
by biotechnologies. It also facilitates drawing upon
the insights of various academic disciplines.
Discipiines that are especiaiiy valuable for gaining
policy insights about biotechnoiogies in a systems
context are ecology, economics, and sociology.
Contrary to a common belief among some non-
economists, economics deals with much more than
private, monetary benefits and costs. Economics is
really about the implications of alternative resource
allocation decisions. This includes both direct and
Indirect effects. It includes both effects that are
measurable in monetary terms and effects for
which monetary measures are not readily available.
Examples of effects that are highly relevant to
systems oriented economic analyses but which
cannot always be measured monetarily include
various environmental or ecological Impacts, as
wel! as some kinds of social impacts.
The nature of s
risks
benefits, costs, and
Transgenic technology research and
development (R&D) in agriculture is most
commonly intended to produce 'benefits' in one or
more of the following areas;
» Increased or less variable output
(yield) per unit of land
» Increased productivity relative to
non-land inputs (e.g., output per
unit of fossil fuel energy inputs or
per unit of chemical pesticide
inputs)

• Decreased costs of production
(e.g., dollars per bushel of com
produced)
• New or enhanced 'quality'
characteristics (e.g., protein
composition)
Therefore, attempts to assess economic
consequences of particular transgenic technologies
are best begun by specifying which one or more of
these 'benefits' the R&D is intended to produce.
New or higher costs associated with
particular biotechnologies may accrue to adopters,
to others in the farm and food system, and to other
individuals and groups. For example, herbicide
tolerant transgenic plants involve higher seed costs
and sometimes may result in lower per acre yields.
Those costs must be weighed against potentially
lower labor, machinery, and chemical pesticide
costs in determining the net impact on farm
profitability. Some agri-businesses involved in
grain handling are likely to experience increased
costs for segregating transgenic and non-
transgenic grains if resistance to transgenic
products continues in major foreign markets.
Those costs may or may not be offset by premiums
that handlers can capture or charges they are able
to assess.
Another kind of costs is described by
economists as 'externality costs'. An extemality
is any action that affects the welfare of, or
opportunities available to, an individual or group
without direct payment or compensation, and may
be positive or negative. Economists involved in
systems analyses of biotechnology applications are
concerned with 'technological' (or physical)
externalities, rather than with 'pecuniary' (or price
effect) extemalities. An example of a technological
external cost would be pollen drift from a transgenic
crop that 'contaminates' a neighbor's organic crop.
(This is a 'technological' externality because there
is a 'physical' alteration in the neighbor's crop.)
Crops grown from transgenic seed stock are not
supposed to qualify for organic certification, and
therefore, organic price premiums. Consequently,
contamination can have severely adverse
economic ramifications for organic farmers, who
are unwilling recipients of the impacts of adoption
by others of transgenic technology.
'Risks' in systems analyses of biotech
nologies generally are those potential costs that, at
best, we can only estimate in rough, probabilistic
terms. Often included here are health and
environmental risks. For example, StarLink™ com
was not approved for human consumption yet
found its way into the human food system in spite
of regulations prohibiting that. The Centers for
Disease Control has subsequently issued a
statement that StarLink™ poses no risk to human
health; however, a response from a scientific panel
questioned the reliability of the test that was used.
The 'precautionarv principle'
How can democratic govemments decide
which transgenic technologies should be approved
for commercial application—given the potential
benefits, costs, and risks for different segments of
society? US policies are based primarily on a
'science-based' approach, in which approval for
commercial application is ultimately given if there is
no compelling proof of harm. This approach is
based on the American philosophy that tends to
view science as progress; this philosophy contrasts
with a somewhat more skeptical view of science in
Europe.
The 'precautionary principle' is based on the
premise that "when an activity raises threats of
harm to human health or the environment,
precautionary measures should be taken even if
some cause-and-effect relationships are not yet
fully established scientifically" (Barrett and Flora,
2000, p. 6). Whereas the US approach tends to
place the burden of proof on those who fear
potential harm, the precautionary principle places
the burden of proof primarily on proponents of
transgenic technology to demonstrate that there is,
in fact, little or no risk of serious harm. Core
elements of the precautionary principle include the
following:
• A primary goal of society is to
protect both the environment and
public health.
• Proactive measures should be taken
toward this goal—even in the face of
scientific uncertainty.

• The burden of demonstrating the
safety of a potentially harmful
technology falls on its developers,
rather than on the public or
government.
• Alternatives must be considered.
• Open, informed, and democratic
processes must be used to make
decisions about the acceptability
of technology, its demonstrated
safety, alternatives, research, and
policy goals as well as the
process to achieve these goals.
(Barrett and Flora, p. 7)
The European Union (EU) emphasizes the
precautionary principle in its regulatory approach to
biotechnology. This approach has been
characterized as "guilty until proven innocent,"
while the US approach is "innocent until proven
guilty" (Ervin, et al., 2000, p. 37). Of course, there
is a wide range of views about how to approach risk
both within the US and within Europe. There are
many in the US who advocate the precautionary
principle here, while there are sizeable numbers in
Europe—particularly within the 'scientific
community'—who feel that the precautionary
principle is too restrictive. What we are talking
about here is differences in values, both among
cultures and among individuals within given
cultures and societies. Science cannot tell us
which 'values' are correct. Consequently, though
scientists may have their own, varying, opinions
about an appropriate regulatory approach, they are
in no position to dictate a philosophy of risk
avoidance to the rest of society.
As a variation of the 'precautionary principle'
approach. Pretty (1999) has suggested a
biotechnology regulatory approach based on six
questions. When the answer to any of these
questions appears to be 'no', then there is great
need for caution and more research. If the answer
appears to be 'yes', then society is able to proceed
with less caution. Pretty's six questions are the
following:
• Does the biotechnology process
only involve gene transfers within
the same or related species?
• Is the biotechnology process fully
contained (i.e., does the
technology involve no release to
the environment of transgenic
organisms)?
• If the transgenic crops are released
to the environment, will they affect
only the target organisms as
predicted?
• Is the likelihood of food toxicity or
antibiotic resistance effects in
transgenic foods as low or lower
than other foodstuffs?
• Is the transgenic product
fundamentally for the public good?
Will it be distributed through public
extension systems?
• Are claims for environmental
benefits arising from biotechnology
use on the farm supported by
practice?
These six questions, based substantially on
the 'precautionary principle', facilitate systematic
thinking about the benefits and risks of
biotechnologies. The framework helps to clarify
that all biotechnologies are not the same, but that
they vary by types and magnitudes of potential
benefits, costs, and risks offered. Consequently,
policy and regulatory bodies that address these
questions about research and commercialization of
various transgenic applications need to work on a
case-by-case basis.
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